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Introduction: Genetic polymorphisms that affect DNA repair 
capacity can modulate the efficacy and toxicity of cytotoxic 
agents. Therefore, the aim of our study was to evaluate the influ-
ence of genetic variability in DNA repair genes on treatment out-
come in patients with malignant mesothelioma (MM) treated with 
 gemcitabine-platinum combination chemotherapy.
Methods: In total, 109 patients with MM were genotyped for 10 
polymorphisms in XRCC1, NBN, RAD51, and XRCC3 genes. The 
influence of selected polymorphisms on tumor response and occur-
rence of treatment-related toxicity was determined by logistic regres-
sion analysis, whereas their influence on survival was estimated by 
Cox proportional hazards model.
Results: There were no associations between the investigated poly-
morphisms and tumor response, but we observed a significant asso-
ciation between XRCC1 399Gln allele and reduced overall survival 
(hazards ratio = 1.70; 95% confidence interval [CI] 1.06–2.73; p = 
0.028). Interaction between XRCC1 399Gln allele and C-reactive pro-
tein levels revealed that carriers of at least one XRCC1 399Gln allele 
with C-reactive protein levels above median had significantly shorter 
overall survival time compared with other patients (12.9 months 
versus 25.3 months, log-rank p < 0.001). We also observed an asso-
ciation between XRCC1 399Gln and lower frequency of leukopenia 
(odds ratio [OR] = 0.25; 95% CI 0.09–0.67; p = 0.006), neutropenia 
(OR = 0.24; 95% CI 0.09–0.68; p = 0.007), and thrombocytopenia 
(OR = 0.27; 95% CI 0.09–0.84; p = 0.024). In addition, NBN 
3474A>C, XRCC3 -316A>G, and Thr241Met polymorphisms 
showed significant associations with treatment-related toxicity.
Conclusions: Our results support the hypothesis that DNA repair 
gene polymorphisms, particularly XRCC1 Arg399Gln, may modify 
the response to gemcitabine-platinum combination chemotherapy 
and, for the first time, show this effect in patients with MM.
Key Words: Malignant mesothelioma, Polymorphism, DNA repair, 
Treatment outcome, Toxicity.
(J Thorac Oncol. 2012;7: 1609–1617)
Malignant mesothelioma (MM) is a rare tumor with an increasing incidence and a very poor prognosis. The 
10-year average incidence in Slovenia is approximately 30 
cases per year (www.slora.si, accessed on November 23, 
2011) with a 1-year survival rate of 33%.1 Recently, there 
have been important developments in the chemotherapy of 
MM, which have improved outcomes and prolonged survival 
of patients with MM. The pemetrexed-cisplatin combination 
chemotherapy has become a standard of care in MM treat-
ment;2 however, other similarly effective regimens, such as 
gemcitabine-cisplatin combination, are widely used.3
Gemcitabine exerts its cytotoxic effect mainly through 
inhibition of DNA synthesis by being incorporated into DNA 
and through inhibition of ribonucleotide reductase M1, result-
ing in a decrease of deoxyribonucleotide pools necessary for 
DNA synthesis. Incorporation of gemcitabine into DNA was 
reported to increase the stability of topoisomerase I cleavage 
complexes, leading to the accumulation of strand breaks.4,5 
Besides, platinum agents covalently bind to DNA, forming 
intrastrand DNA adducts or interstrand DNA crosslinks, which 
may also lead to generation of DNA strand breaks.6 The syn-
ergistic cytotoxic effect of gemcitabine-cisplatin combination 
was observed in vitro7 and it was suggested that this combina-
tion increases the accumulation of DNA strand breaks in MM 
cell lines.8 These findings suggest that mechanisms involved 
in the repair of DNA strand breaks might play an important 
role in the response to gemcitabine-platinum treatment.
Single-strand breaks (SSBs) are repaired in a multistep 
process of the base-excision repair (BER) pathway. The 
central molecule of this pathway seems to be a scaffold protein 
x-ray repair crosscomplementing protein 1 (XRCC1), which 
coordinates repair of SSBs through interactions with other BER 
proteins.9 Inadequate repair of SSBs because of a deficient BER 
mechanism can lead to more lethal double-strand breaks (DSBs).
The main mechanism involved in a high-fidelity repair 
of DSBs is the homologous recombination repair (HRR) path-
way. The initial step is the recognition of DNA DSBs by mei-
otic recombination 11/RAD50/nibrin (MRE11/RAD50/NBN) 
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/12/0710-1609
DNA Repair Polymorphisms and Treatment Outcomes 
of Patients with Malignant Mesothelioma Treated with 
Gemcitabine-Platinum Combination Chemotherapy
Nina Erčulj, BSc,* Viljem Kovač, PhD, MD,† Julija Hmeljak, PhD,‡ Alenka Franko, PhD, MD,§  
Metoda Dodič-Fikfak, PhD, MD,§ and Vita Dolžan, PhD, MD*
*Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, 
University of Ljubljana, Ljubljana, Slovenia; †Department of Radiotherapy, 
Institute of  Oncology Ljubljana, Ljubljana, Slovenia; ‡Faculty of Health 
Sciences, University of Primorska, Izola, Slovenia; and §Clinical Institute 
of Occupational Medicine, University Medical Centre, Ljubljana, Slovenia.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Vita Dolžan, PhD, MD, Pharmacogenetics 
Laboratory, Institute of Biochemistry, Faculty of Medicine, University of 
Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia. E-mail: vita.dolzan@
mf.uni-lj.si
Journal of Thoracic Oncology
7
10
© 2012 by the International Association for the Study of Lung Cancer
1556-0864
JTO
202197
DNA Repair Polymorphisms in Malignant Mesothelioma
Erčulj et al.
2012
October
00
00
10.1097/JTO.0b013e3182653d31
Anjana
J Thorac Oncol
ORIGINAL ARTICLE
1610 Copyright © 2012 by the International Association for the Study of Lung Cancer
Erčulj et al. Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012
complex, followed by cleavage of 3ʹ ends of the DSB to form 
single-stranded tails, which invade the intact homologous 
DNA double helix. The RAD51 protein together with adaptor 
proteins, such as XRCC3, plays a central role in this process 
by facilitating initial steps of strand invasion. The 3ʹ-single-
stranded tails are extended by DNA polymerase and the result-
ing Holliday junctions are resolved to yield two intact DNA 
molecules.
A growing body of evidence has suggested that DNA 
repair mechanism can modulate the anticancer activity of 
cytotoxic agents and, therefore, genetic polymorphisms that 
affect DNA repair capacity might influence the efficacy and 
toxicity of gemcitabine-platinum combination chemotherapy 
in patients with MM. There are some reports regarding the 
influence of BER polymorphisms on treatment response to 
gemcitabine-platinum combination chemotherapy,10,11 but evi-
dence of the association between HRR polymorphisms and 
treatment outcome is insufficient. Moreover, the influence of 
BER or HRR polymorphisms on treatment outcome in MM 
patients treated with gemcitabine-platinum combination che-
motherapy has not been established so far.
The aim of our study was to evaluate the influence of 
single-nucleotide polymorphisms (SNPs) in XRCC1, NBN, 
RAD51, and XRCC3 genes and their corresponding haplo-
types on tumor response, survival, and treatment-related tox-
icity in patients with MM treated with gemcitabine-platinum 
combination chemotherapy.
PATIENTS AND METHODS
Study Design
Separate case-control studies were designed for the 
analysis of tumor response and toxicity. For analysis of tumor 
response, cases were defined as patients with stable disease 
(SD) or progressed disease (PD), whereas controls were defined 
as patients with complete response (CR) or partial responses 
(PR) to treatment. For toxicity analyses, cases were defined as 
patients who developed specific treatment-related toxicities, 
whereas controls were defined as patients who did not develop 
that toxicity. For survival analysis, a Cox model was used.
Patients
The study group consisted of 109 patients with his-
tologically confirmed MM. All the patients were diagnosed 
between 1997 and 2010 at the University Clinic of Pulmonary 
and Allergic Diseases in Golnik, Slovenia and at the University 
Clinical Centre Maribor, Slovenia. The inclusion criteria for 
the selection of patients and details of clinical data collection 
were described previously.12
All the patients who were alive at the time of data collection 
gave their written informed consent to participate in the study. 
The study was approved by the Slovenian Ethics Committee for 
Research in Medicine (approval ref. no. 04/02/09) and was car-
ried out according to the Declaration of Helsinki.
Treatment
All patients with MM were treated at the Institute of 
Oncology, Ljubljana, Slovenia; therefore, treatment, outcome 
assessment, and follow-up were centralized for all subjects. 
Patients were treated with gemcitabine in combination with 
a platinum agent according to one of the two following regi-
mens: gemcitabine in prolonged infusion in combination with 
cisplatin or carboplatin;13 or gemcitabine in standard infusion 
in combination with cisplatin.14 We also included patients who 
received gemcitabine-platinum combination chemotherapy as 
a part of multimodality treatment with surgery and/or pallia-
tive radiotherapy.
Response, Survival, and Toxicity Assessment
Tumor response was evaluated as described previously.14 
Progression-free survival (PFS) time was defined as time 
from day 1 of first-line gemcitabine-platinum chemotherapy 
to the day of documented disease progression according to the 
Response Evaluation Criteria In Solid Tumors or to death from 
any cause, whichever occurred first. Overall survival (OS) 
time was defined as time from day 1 of first-line gemcitabine-
platinum chemotherapy to death from any cause. Patients 
without documented progression or death at the last follow-
up evaluation (September 2011) were censored at that time. 
Hematologic toxicities, nephrotoxicity, alopecia, and nausea/
vomiting were evaluated according to the National Cancer 
Institute-Common Toxicity Criteria, version 4.0 (http://ctep.
info.nih.gov/reporting/ctc.html, accessed on November 23, 
2011). Hematologic toxicities were defined by decreased 
serum hemoglobin levels (anemia), decline of: white blood 
cells (leukopenia), neutrophil (neutropenia), and platelet 
count (thrombocytopenia). Nephrotoxicity was defined by 
elevated levels of serum creatinine concentration. The high-
est grade of individual toxicity during first-line chemotherapy 
was chosen as the endpoint for toxicity analyses. Toxicities 
of grade 2 or higher were considered as clinically relevant. 
Thrombocytopenia and nephrotoxicity was categorized only 
as present or absent because of the very low frequency of 
grade 2 or higher toxicities in the study group.
SNP Selection
SNP search in XRCC1, NBN, RAD51, and XRCC3 genes 
was assessed using the scientific literature database PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), National Center for 
Biotechnology Information SNP database,15 and HapMap 
database.16 Previously investigated functional SNPs and/or 
putatively functional SNPs that tag haplotype blocks with 
minor allele frequencies greater than 5% were selected. The 
exploration of possible SNPs’ functionality and haplotype-
tagging was carried out by Web-based SNP prediction tools.17,18
DNA Extraction and Genotyping
Tumor tissue specimens or peripheral blood samples 
were collected at the time of diagnosis. Tumor tissue speci-
mens were routinely formalin fixed and paraffin embedded. 
Genomic DNA from formalin-fixed and paraffin-embedded 
tissue was extracted as previously described.19 A Qiagen 
FlexiGene kit (Qiagen, Hilden, Germany) was used for the 
extraction of genomic DNA from frozen whole-blood samples.
Genotypes of XRCC1 were determined by TaqMan SNP 
genotyping method (Applied Biosystems, Foster City, CA), 
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as described previously.20 Genotyping of NBN, RAD51, and 
XRCC3 was carried out using a fluorescence-based competi-
tive allele-specific (KASPar) assay (KBiosciences, Herts, 
United Kingdom).21 To ensure the data quality, 10% of the 
samples were genotyped in duplicates, and samples with dis-
cordant results were excluded from the data analysis.
Statistical Analysis
The median was used to present central tendency, 
whereas the range (minimum–maximum) was a measure of 
variability. For each SNP, deviations of genotype frequency 
distribution between blood and tumor samples, as well as 
deviations of genotype frequency distribution from those 
expected under Hardy-Weinberg equilibrium (HWE) were 
assessed using the standard χ2 test.
A dominant genetic model was used in all statistical 
analyses. The number of different treatment-related toxicities 
in individual patients was compared between genotype groups 
using the nonparametric Mann-Whitney U test. The influences 
of investigated SNPs on tumor response and occurrence of 
treatment-related toxicities were examined by logistic regres-
sion analysis to calculate odds ratios (ORs) and their respec-
tive 95% confidence intervals (CIs).
Survival times were calculated and compared using the 
Kaplan–Meier method. Survival curves were estimated using 
the Cox proportional hazards model, and hazard ratios (HRs) 
with their 95% CIs were determined. All potential clinical and 
treatment predictors12 were independently analyzed for their 
influence on tumor response, PFS, OS, and treatment-related 
toxicity. For predictors with p values less than 0.050 in the uni-
variable analysis forward selection was applied, and only signif-
icant predictors were included in the final multivariable model.
Stratification was performed to investigate possible con-
founding or effect modification of different variables. In case 
of observed effect modification, the regression model using 
dummy variables was introduced. All statistical analyses 
were carried out using the Statistical Package for the Social 
Sciences (SPSS) for Windows, version 19 (IBM Corporation, 
Armonk, NY).
On the basis of genotype data, haplotypes were recon-
structed and analyzed using the Thesias program,22 as 
described previously.14 The influence of investigated haplo-
types on tumor response, OS, PFS, and treatment-related tox-
icity was assessed. All statistical tests were two sided and the 
level of significance for all statistical analyses was set to 0.050.
RESULTS
Patients
The study included 109 patients with either pleural 
(n = 99) or peritoneal (n = 10) MM. Demographic and clinical 
characteristics of the study group are summarized in Table 1. 
The study group consisted of 83 men (76.1%) and 26 women 
(23.9%) with a median age of 62 years (range, 32–83 years) at 
the time of diagnosis (Table 1). All patients received gemcitabine 
in combination with platinum agents during the first-line 
setting. Most of these patients (n = 105, 96.3%) were treated 
with gemcitabine in prolonged infusion in combination with a 
platinum agent, and 81 patients (74.3%) received six cycles of 
first-line chemotherapy. Eighteen patients (16.5%) underwent 
multimodality treatment. Forty-eight patients (43.6%) received 
second-line chemotherapy and, among them, 17 (35.4%) 
received six cycles of chemotherapy. As a general rule, patients 
who previously responded to treatment with gemcitabine in 
prolonged infusion in combination with a platinum agent were 
considered for reinduction with the same or similar chemotherapy 
schedule (n = 30). Other treatment options included combination 
of pemetrexed with platinum agent (n = 12), navelbine (n = 6), or 
palliative radiotherapy (n = 14).
Patients who underwent surgical resection of tumor 
before chemotherapy (n = 4, 3.7%) were not evaluated in the 
tumor response analysis. Among 105 assessable patients for 
tumor response analysis, there were five patients (4.8%) with 
CR and 47 (44.8%) with PR, together accounting for an over-
all response rate of 49.6%. SD was observed in 47 patients 
(44.8%) and six patients had progressed disease (5.7%). At 
TABLE 1. Demographic and Clinical Characteristics of  
Patients with Malignant Mesothelioma Treated with  
Gemcitabine-Platinum Combination Chemotherapy (N = 109)
Characteristic n (%)
Median 
(Range)
Age, yrs 62 (32–83)
Sex
Male 83 (76.1)
Female 26 (23.9)
Asbestos exposurea 78 (71.6)
Smoking statusb
Smoker 47 (43.1)
Nonsmoker 60 (55.0)
ECOG performance status
<2 76 (69.7)
≥2 33 (30.3)
Histological type
Epitheloid 79 (72.4)
Biphasic 17 (15.6)
Sarcomatoid 10 (9.2)
Not characterized 3 (2.8)
TNM stage
I or II 36 (33.0)
III or IV 63 (57.8)
Not characterized 10 (9.2)
Percentage of weight loss, %c 2 (0-22)
Pain at diagnosisc 74 (67.9)
Hemoglobin level at diagnosis, g/Ld 131 (88–167)
White blood cell count at diagnosis, *109/Ld 8.6 (3.1-19.8)
LDH level at diagnosis, μkat/L 2.8 (1.5-109.0)
CRP level at diagnosis, mg/L 26 (0-339)
aAsbestos exposure was defined as occupational or environmental exposure.12
bData missing for two (1.8%) patients.
cData missing for three (2.8%) patients.
dData missing for one (0.9%) patient.
CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology group; LDH, 
lactate dehydrogenase; TNM, tumor-nodes-metastasis.
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the date of the last follow-up, 102 patients (93.6%) had expe-
rienced disease progression and 93 had died (85.3%). Median 
PFS time was 8 months (range, 0–63 months), whereas OS 
time was 16 months (range, 1–85 months). Median follow-up 
time for living patients was 16 months (range, 4–85 months).
One hundred patients (91.8%) developed at least one 
toxic effect and the number of different treatment-related 
toxicities in individual patients ranged from one to six. 
Prevalence of treatment-related toxicities was as follows: ane-
mia of grade 2 or higher (n = 61; 56.0%), leukopenia grade of 
2 or higher (n = 43; 39.4%), neutropenia of grade 2 or higher 
(n = 57; 52.3%), thrombocytopenia of grade 1 or higher 
(n = 17; 15.6%), alopecia of grade 2 or higher (n = 63; 57.8%), 
and nausea/vomiting of grade 2 or higher (n = 44; 40.4%).
Genotyping Analysis
According to the SNP selection criteria, 10 SNPs in 
XRCC1, NBN, RAD51, and XRCC3 genes were selected, and 
their genotype frequencies in patients with MM are presented 
in Table 2. All genotype frequencies were consistent with 
HWE and with frequencies reported for other white popula-
tion in National Center for Biotechnology Information SNP 
database, except for RAD51 -61G>T SNP, which showed 
significant deviation from HWE (p = 0.016) as well as from 
published genotype frequencies in the white population 
(p = 0.023). Therefore, RAD51–61G>T SNP was excluded 
from further statistical analysis.
Because DNA samples of patients with MM were 
obtained either from tumor samples (n = 42, 38.5%) or periph-
eral blood lymphocytes (n = 67, 61.5%), both DNA sources 
were tested for possible genotype discrepancies. In 10 patients 
who had both DNA sources available, genotypes of all inves-
tigated SNPs were in complete concordance between germ-
line and tumor DNA. Moreover, we observed no statistically 
significant differences of genotype-frequency distributions 
between tumor and blood samples or deviations from HWE in 
the group of tumor samples (see Table, Supplemental Digital 
TABLE 2.  Influence of BER and HRR Polymorphisms on Tumor Response and Survival Assessed in Univariable Analyses in 
Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy (N = 109)
Polymorphism Genotype n
Patients Tumor responsea PFS OS
(%) OR (95% CI)b p HR (95% CI)c p HR (95% CI)c p
XRCC1 Arg194Trp
rs1799782
Arg/Arg 91 (83.5) 1 1 1
Arg/Trp 18 (16.5) 0.73 (0.25–2.13) 0.560 0.78 (0.45–1.34) 0.372 0.79 (0.46–1.36) 0.394
Trp/Trp 0 (0.0)
XRCC1 Arg399Gln
rs25487
Arg/Arg 39 (35.8) 1 1 1
Arg/Gln 58 (53.2) 0.68 (0.30–1.52) 0.343 1.11 (0.73–1.67) 0.637 1.18 (0.77–1.82) 0.443
Gln/Gln 12 (11.0)
NBN Glu185Gln
rs1805794
Glu/Glu 17 (15.6) 1 1 1
Glu/Gln 44 (40.4) 1.56 (0.55–4.55) 0.405 0.73 (0.43–1.26) 0.257 0.76 (0.43–1.35) 0.350
Gln/Gln 48 (44.0)
NBN 1197A>G
rs709816
A/A 45 (41.3) 1 1 1
A/G 46 (42.2) 0.95 (0.44–2.08) 0.907 1.08 (0.73–1.62) 0.694 0.90 (0.60–1.36) 0.624
G/G 18 (16.5)
NBN 3474A>C
rs1063054
A/A 47 (43.1) 1 1 1
A/C 45 (41.3) 0.95 (0.48–2.08) 0.910 1.13 (0.75–1.68) 0.565 0.91 (0.60–1.38) 0.657
C/C 17 (15.6)
RAD51 -98G>C
rs1801320
G/G 90 (82.6) 1 1 1
G/C 17 (15.6) 2.50 (0.87–7.14) 0.090 0.88 (0.53–1.48) 0.636 0.85 (0.48–1.51) 0.583
C/C 2 (1.8)
RAD51 1522T>G
rs12593359
T/T 24 (22.0) 1 1 1
T/G 55 (50.5) 1.96 (0.78–5.00) 0.152 0.98 (0.61–1.56) 0.920 1.16 (0.71–1.89) 0.560
G/G 30 (27.5)
XRCC3 -316A>G
rs1799794
A/A 61 (56.3) 1 1 1
A/G 44 (40.4) 1.04 (0.48–2.27) 0.910 1.18 (0.81–1.74) 0.413 1.14 (0.75–1.72) 0.545
G/G 4 (3.6)
XRCC3 Thr214Met
rs861539
Thr/Thr 43 (39.4) 1 1 1
Thr/Met 43 (39.4) 0.64 (0.29–1.41) 0.266 1.15 (0.77–1.72) 0.493 1.09 (0.71–1.67) 0.690
Met/Met 23 (21.1)
aComplete or partial response versus stable or progressed disease. Data on tumor response was available for 105 (96.3%) patients.
bORs, 95% CIs, and P values were calculated by univariable logistic regression and the dominant genetic model was used.
cHRs, 95% CIs, and P values were calculated by univariable Cox proportional hazards regression and the dominant genetic model was used.
BER, base-excision repair; CI, confidence interval; HR, hazard ratio; HRR, homologous recombination repair; OR, odds ratio; OS, overall survival; PFS, progression-free survival.
1613Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 10, October 2012 DNA Repair Polymorphisms in Malignant Mesothelioma
Content 1, http://links.lww.com/JTO/A321, which shows 
comparison of distributions of genotype frequencies between 
blood and tumor samples and deviations from HWE in the 
group of tumor samples), indicating no loss of heterozygosity.
Tumor Response Analysis
The influence of XRCC1, NBN, RAD51, and XRCC3 
SNPs on tumor response was determined by univariable logis-
tic regression analysis. No significant associations were found 
between investigated SNPs and patients who achieved CR or 
PR (Table 2).
Survival Analysis
The influence of XRCC1, NBN, RAD51, and XRCC3 
SNPs on PFS and OS was determined by univariable Cox 
proportional hazards model, but no significant associa-
tions between investigated SNPs and survival were observed 
(Table 2). Among the clinical variables with evidence of prog-
nostic impact, sarcomatoid histological type (HR = 2.46; 95% 
CI 1.16–5.21; p = 0.019), C-reactive protein (CRP) level at the 
time of diagnosis (HR = 1.01; 95% CI 1.00–1.01; p < 0.001), 
number of first-line chemotherapy cycles (HR = 0.74; 95% 
CI 0.61–0.90; p = 0.002), and number of second-line che-
motherapy cycles (HR = 0.86; 95% CI 0.78–0.95; p = 0.003) 
remained significant predictors of OS in multivariable model. 
When this model was used, XRCC1 Arg399Gln SNP showed 
a statistically significant influence on OS (HR = 1.70; 95% CI 
1.06–2.73; p = 0.028).
Sarcomatoid histological type and number of second-line 
chemotherapy cycles did not substantially influence hazard of 
dying for XRCC1 339 Arg/Arg versus Arg/Gln+Gln/Gln gen-
otypes, but the adjustment for CRP level at the time of diagno-
sis and number of first-line chemotherapy cycles changed HR 
from 1.18 (95% CI 0.77–1.82) in univariable analysis to 1.40 
(95% CI 0.91–2.18) and 1.51 (95% CI 0.95–2.39), respec-
tively (see Table, Supplemental Digital Content 2, http://links.
lww.com/JTO/A322, which demonstrates changes in HR for 
XRCC1 Arg399Gln SNP after adjustment for clinical predic-
tors). Stratification of association between XRCC1 Arg399Gln 
SNP and OS by CRP level at the time of diagnosis and number 
of first-line chemotherapy cycles suggested a possible interac-
tion between XRCC1 Arg399Gln SNP and CRP level at the 
time of diagnosis (see Tables, Supplemental Digital Content 
3 and 4, http://links.lww.com/JTO/A323 and http://links.lww.
com/JTO/A324, which demonstrate stratification of associa-
tion between XRCC1 Arg399Gln SNP and OS by CRP level at 
the time of diagnosis and number of first-line chemotherapy 
cycles). Using Cox proportional hazards model, a significant 
interaction between XRCC1 Arg399Gln SNP and CRP level 
at diagnosis as a dichotomous variable was observed (HR = 
2.52; 95% CI 1.04–6.08; p = 0.040) (Table 3).
Carriers of at least one XRCC1 399Gln allele, who had 
above-median CRP levels (n = 35, 32.1%) relative to other 
patients had significantly shorter median OS time (10.0 
months versus 17.0 months, log-rank p < 0.001) (Fig. 1) 
and significantly worse OS probability in the multivariable 
model adjusted for sarcomatoid histological type, number of 
first-line chemotherapy cycles, and number of second-line 
chemotherapy cycles (HR = 2.47; 95% CI 1.56–3.92; 
p < 0.001) (Fig. 1). Carriers of at least one XRCC1 399Gln 
allele, who had above-median CRP levels received similar 
chemotherapy combination regimens in the second-line 
setting compared with other patients (p = 0.297). Besides, 
we did not observe any influence of the type of second-line 
chemotherapy regimen on OS (log-rank p = 0.462).
Toxicity Analysis
In univariable logistic regression analysis only 
XRCC1 Arg399Gln, NBN 3474A>C, XRCC3 -316A>G, 
and XRCC3 Thr241Met polymorphisms influenced 
 treatment-related toxicity (Table 4). None of the inves-
tigated polymorphisms were associated with anemia of 
grade 2 or higher or nephrotoxicity of grade 1 or higher (p 
≥ 0.050 for all associations).
TABLE 3. Influence of Interaction between XRCC1 
 Arg399Gln Polymorphism and CRP Levels at Diagnosis as 
Dichotomous Variable on Overall Survival in Cox Proportional 
Hazards Model in Patients with Malignant Mesothelioma 
Treated with Gemcitabine-Platinum Combination Chemo-
therapy (N = 109)
Variable HR (95% CI) p
XRCC1 399Arg/Arg versus 399Arg/Gln+Gln/Gln 0.81 (0.46–1.45) 0.485
CRP level <median versus ≥median 0.95 (0.47–1.94) 0.897
XRCC1 Arg399Gln*CRP level 2.52 (1.04–6.08) 0.040
HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein.
FIGURE 1. Overall survival in the function of combination 
of CRP levels and XRCC1 Arg399Gln genotype in malignant 
mesothelioma patients treated with gemcitabine-platinum 
combination chemotherapy (N = 109). CRP, C-reactive 
protein; CRPhigh, above-median CRP level; CRPlow, under-
median CRP level.
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Among the investigated clinical parameters, female sex, 
age, nonsarcomatoid histology, and higher number of first-line 
chemotherapy cycles were identified as independent predictors 
of different treatment-related toxicities in the multivariable 
model (Table 5). When this model was used, XRCC1 399Arg/
Gln+Gln/Gln genotypes remained significantly but negatively 
associated with leukopenia of grade 2 or higher (OR = 0.25; 
95% CI 0.09–0.67; p = 0.006), neutropenia of grade 2 or 
higher (OR = 0.24; 95% CI 0.09–0.68; p = 0.007), and 
thrombocytopenia of grade 1 or higher (OR = 0.27; 95% CI 
0.09–0.84; p = 0.024). In addition, the following association 
of HRR SNPs with treatment-related toxicity remained 
significant in the multivariable model: NBN 3474A/C+C/C 
genotypes with increased odds ratio of alopecia of grade 
2 or higher (OR = 2.81; 95% CI 1.13–7.00; p = 0.027), 
XRCC3 -316A/G+G/G genotypes with odds ratio below one 
of thrombocytopenia of grade 1 or higher (OR = 0.18; 95% 
CI 0.05–0.68; p = 0.012), and XRCC3 241Thr/Met+Met/Met 
genotypes with odds below one of nausea/vomiting of grade 2 
or higher (OR = 0.34; 95% CI 0.14–0.85; p = 0.021).
We also determined the influence of investigated poly-
morphisms on the number of different treatment-related tox-
icities in individual patients. A significantly lower number of 
different toxicities was observed in carriers of at least one 
XRCC1 399Gln compared with patients with wild-type geno-
type (Kendal τ = -0.192, p = 0.026), whereas the number of 
different toxicities was higher in carriers of at least one NBN 
3474C allele compared with patients with wild-type genotype 
(Kendal τ = 0.228, p = 0.008).
Haplotype Analysis
Haplotype analysis was carried out to evaluate the 
combined effect of BER and HRR SNPs on treatment 
outcome in patients with MM. Three 2-SNP XRCC1 
(Arg194Trp, Arg399Gln) haplotypes, three 3-SNP NBN 
(Glu185Gln, 1197A>G, 3474A>C) haplotypes, three 2-SNP 
RAD51 (-98G>C, 1522T>G) haplotypes, and three 2-SNP 
XRCC3 (-316A>G, Thr241Met) haplotypes had a frequency 
greater than 5% (see Table, Supplemental Digital Content 
5, http://links.lww.com/JTO/A325, which shows haplotype 
frequencies). There were no significant associations between 
the investigated haplotypes and tumor response, PFS, or OS (data 
not shown). Nevertheless, carriers of XRCC1 CA haplotype 
had significantly lower odds ratio of leukopenia of grade 2 
or higher (OR = 0.53; 95% CI 0.29–0.98; p = 0.044) and 
thrombocytopenia of grade 1 or higher (OR = 0.39; 95% CI 
TABLE 4.  Influence of BER and HRR Polymorphisms on Occurrence of Treatment-Related Toxicities Assessed in Univariable 
Analyses in Patient with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy (N = 109)
Polymorphism
Leukopeniaa
grade ≥2
Neutropenia
grade ≥2
Thrombocytopeniaa
grade ≥2
Alopeciab
grade ≥2
Nausea/vomitingb
grade ≥2
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
XRCC1 Arg399Gln
 Arg/Arg versus 
Arg/Gln+Gln/Gln
0.40
(0.18–0.90)
0.027 0.40
(0.18–0.90)
0.027 0.33
(0.11–0.95)
0.039 0.90
(0.40–2.02)
0.797 0.48
(0.21–1.08)
0.075
NBN 3474A>C
 A/A versus
A/C+C/C
1.70
(0.77–3.77)
0.189 2.33
(1.08–5.06)
0.032 1.97
(0.64–6.04)
0.237 2.63
(1.19–5.82)
0.017 1.36
(0.62–2.97)
0.448
XRCC3 -316A>G
 A/A versus
A/G+G/G
1.15
(0.53–2.49)
0.725 0.85
(0.40–1.81)
0.617 0.22
(0.06–0.81)
0.023 1.81
(0.82–3.97)
0.141 1.95
(0.89–4.26)
0.094
XRCC3 Thr241Met
 Thr/Thr versus
Thr/Met+Met/Met
0.81
(0.37–1.79)
0.607 1.26
(0.58–2.71)
0.560 1.20
(0.41–3.53)
0.741 0.81
(0.37–1.80)
0.609 0.34
(0.18–0.88)
0.023
ORs, 95% CIs, and p values were calculated by univariable logistic regression. Bold characters indicate statistically significant results.
aToxicity data missing for one (0.9%) patient.
bToxicity data missing for two (1.8%) patients.
BER, base-excision repair; CI, confidence interval; HRR, homologous recombination repair; OR, odds ratio.
TABLE 5. Influence of Clinical and Treatment Characteristics 
on the Occurrence of Treatment-Related Toxicity Assessed in  
Multivariable Analysis in Patients with Malignant Mesothelioma 
Treated with Gemcitabine-Platinum Combination Chemo-
therapy (N = 109)
Treatment-Related 
toxicity Characteristic OR (95% CI) p
Leukopenia grade ≥2a Female sex 3.45 (1.13–10.53) 0.030
Number of first-line 2.10 (1.12–3.94) 0.021
Neutropenia grade ≥2 Sarcomatoid histology 0.11 (0.01–0.92) 0.042
Number of first-line 
chemotherapy cycles
1.58 (1.03–2.42) 0.035
Alopecia grade ≥2b Sarcomatoid histology 0.15 (0.03–0.79) 0.025
Number of first-line 
chemotherapy cycles
1.52 (1.02–2.27) 0.042
Nausea/vomiting 
grade ≥2b
Female sex 3.24 (1.08–9.70) 0.035
Age 0.93 (0.88–0.98) 0.004
ORs, 95% CIs, and p values were calculated by multivariable logistic regression 
model including sex, age, histological type, and number of first-line chemotherapy cycles.
aToxicity data missing for one (0.9%) patient.
bToxicity data missing for two (1.8%) patients.
CI, confidence interval; OR, odds ratio.
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0.16–0.95; p = 0.037) compared with patients with the wild-
type XRCC1 CG haplotype. We also observed an association 
between XRCC3 GC haplotype and lower frequency of 
thrombocytopenia of grade 1 or higher compared with XRCC3 
AT haplotype (OR = 0.13; 95% CI 0.02–0.75; p = 0.022).
DISCUSSION
In this study, we evaluated the effects of ten SNPs in 
BER and HRR pathway on treatment outcome in patients 
with MM treated with gemcitabine-platinum combination 
chemotherapy. None of the investigated polymorphisms influ-
enced tumor response or PFS. We also observed a highly 
significant decrease of OS probability in carriers of XRCC1 
399Gln allele, who had above-median CRP levels at the time 
of diagnosis. Our results are in agreement with the current 
understanding of XRCC1 involvement in platinum-based che-
motherapy. Several studies, which investigated the influence 
of XRCC1 SNPs on treatment outcome in cancer patients 
treated with different platinum-based chemotherapy regimens, 
showed a significant association of XRCC1 399Gln allele with 
worse clinical outcomes.23–27 Among five studies published to 
date, which included gemcitabine-platinum treated NSCLC 
patients, three of them reported shorter median OS time11,28 or 
lower response rates in carriers of XRCC1 399Gln allele.11,29 
On the contrary, Giachino et al.30 reported a borderline sig-
nificant opposing effect of XRCC1 399Gln variant on OS, 
whereas de las Peñas et al.10 showed a favorable prognosis of 
patients with heterozygous genotype relative to patients with 
both homozygous genotypes. However, none of these studies 
investigated interactions between XRCC1 Arg399Gln poly-
morphism and clinical prognostic factors.
It was suggested that XRCC1 protein is involved in both 
BER and SSB repair pathways, and may therefore play a role 
in the response to gemcitabine-platinum combination therapy. 
Because XRCC1 Arg399Gln SNP is located in the poly-(ADP-
ribose) polymerase 1-binding domain, it was suggested that 
this SNP affects the protein’s function. Its functional signifi-
cance was shown by cytogenetic challenge assay, indicating 
a defective BER function in X-irradiated cells homozygous 
for the XRCC1 399Gln variant.31 These observations were also 
confirmed in vivo, as carriers of XRCC1 399Gln variant allele 
were reported to have higher levels of DNA damage compared 
with wild-type individuals.32,33 These reports, together with 
our findings, support the hypothesis that DNA repair poly-
morphisms, contributing to suboptimal DNA repair capacity, 
result in more biologically aggressive tumors and promote 
cancer progression rather than influence response to genotoxic 
agents through inefficient repair.34,35 This assumption was fur-
ther confirmed by the interaction between XRCC1 Arg399Gln 
SNP and CRP levels influencing OS probability in our study. 
Decreased DNA repair capacity, caused by the XRCC1 399Gln 
variant, and high CRP levels might be both associated with 
more aggressive tumors;35,36 therefore, a highly significant 
decrease of OS probability in patients with XRCC1 399Gln 
allele, who had high CRP levels at diagnosis, was expected. 
Nevertheless, CRP level at diagnosis and XRCC1 Arg399Gln 
polymorphisms by themselves did not have a statistically sig-
nificant impact on survival in multivariate analysis including 
interaction parameter. Because of wide confidence intervals 
which included one, these findings are preliminary and need 
to be validated in larger cohorts of similarly treated patients.
Toxicity analyses carried out in our study showed sig-
nificantly decreased odds of leukopenia, neutropenia, and 
thrombocytopenia as well as significantly lower numbers of 
different treatment-related toxicities in carriers of polymor-
phic XRCC1 399Gln allele. As found in single SNP analysis, 
carriers of the XRCC1 CA haplotype, containing polymor-
phic 399Gln allele, had fewer leukopenia and thrombocyto-
penia events than patients with wild-type CG haplotype. In 
concordance with our results, other studies also reported an 
association between decreased susceptibility to treatment-
related toxicity and XRCC1 399Gln allele.37–39 Nevertheless, 
these associations are not in agreement with the functional 
significance of XRCC1 Arg399Gln SNP, as decreased DNA 
repair capacity is expected to result in a higher frequency 
of toxic effects in normal tissues. A possible explanation of 
these discrepant findings is that XRCC1 Arg399Gln SNP is 
not the casual variant, but is rather in linkage disequilibrium 
with another functional polymorphism. A study supporting 
this assumption showed a significant association of XRCC1 
Arg399Gln SNP with protein expression in advanced cervical 
carcinoma patients.23
Moreover, polymorphisms of HRR pathway also 
showed significant associations with treatment-related toxici-
ties in patients with MM treated with gemcitabine-platinum 
combination chemotherapy. We observed significantly higher 
odds of neutropenia and alopecia as well as higher number of 
different treatment-related toxicities in carriers of NBN 4374C 
allele relative to patients with the wild-type genotype. To date, 
NBN 4374A<C SNP was shown to increase susceptibility to 
lung cancer,40 but its association with clinical outcome has not 
been determined yet. Because the functional significance of 
NBN 4374A<C SNP is also unknown, the biologic interpre-
tation of this data is difficult. This SNP is located in the 3ʹ 
untranslated region of NBN gene and several micro-RNA–
binding sites were predicted in this region,17 suggesting a pos-
sible influence of 4374A<C SNP on the translational efficacy 
of the NBN gene. Therefore, further investigations are needed 
to confirm the clinical relevance and the biological function 
of this SNP.
Our study showed no association of RAD51 -98G>C 
and 1522T>G SNPs with clinical outcome in patients with 
MM, whereas -61G>T SNP showed a significant deviation 
from HWE, and was thus excluded from statistical analyses. 
In contrast to our results, RAD51 -98G>C polymorphism 
showed a significant prognostic role in NSCLC patients 
treated with a platinum agent in combination with gemcitabine 
and taxanes,41 but another study reported no association of 
this polymorphism with treatment outcome in platinum-
based treated breast cancer patients.42 The lack of association 
between RAD51 -98G>C SNP and treatment outcomes 
in our study might be because of the low frequency of the 
polymorphic allele and a relatively small study population, 
leading to insufficient statistical power to detect significant 
associations.
Both SNPs, investigated in the XRCC3 gene, influenced 
treatment-related toxicity in our group of patients with MM. 
We observed significant associations between polymorphic 
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XRCC3 -316G allele and decreased odds of thrombocytope-
nia, as well as between polymorphic XRCC3 241Met allele 
and decreased odds of nausea/vomiting. The influence of 
XRCC3 SNPs on treatment-related toxicity was confirmed 
in haplotype analysis and demonstrated a significant associa-
tion between XRCC3 GC haplotype and increased frequency 
of thrombocytopenia. Similar results were obtained in other 
studies, where XRCC3 241Met allele showed protective 
effects toward radiation-induced toxicity in normal tissue43 
and liver toxicity in acute myeloid leukemia patients.44 The 
only study investigating the influence of XRCC3 -316A>G 
SNP on treatment-related toxicity reported that the XRCC3 
-316G allele was significantly associated with higher level of 
radiation-induced toxicity, but this association did not remain 
significant in the multivariable model.45
The analysis of potential clinical predictive and prognos-
tic factors in this study showed an important role for histologi-
cal type, CRP level at diagnosis, and number of first-line and 
second-line chemotherapy cycles in the survival of patients 
with MM. Compared with our previous study, the significance 
of the association between CRP level and OS was even higher 
in this cohort of patients with updated survival data, indicat-
ing a potential clinical importance of CRP levels at diagno-
sis as a prognostic marker.46,47 Our favorable experience and 
a recent report on reinduction of pemetrexed-based second-
line chemotherapy indicated that at least some patients did not 
develop resistance to the prior chemotherapy combination.13,48 
However, we did not observe the difference in OS between 
patients who received gemcitabine-based or pemetrexed-
based combination chemotherapy in the second-line setting. 
In addition, we identified female sex, younger age, histological 
type, and number of first-line chemotherapy cycles as predic-
tors of treatment-related toxicity. As gemcitabine pharmaco-
kinetics was shown to be significantly influenced by sex,49 
the increased frequency of treatment-related toxicity among 
women was expected. Similar to our findings, the decreased 
frequency of chemotherapy-induced nausea/vomiting in older 
patients was reported in another study.50 However, the associa-
tion between histological type and treatment-related toxicity 
has not been investigated yet.
Despite several significant findings reported in this 
study, some potential limitations should be taken into consid-
eration. We are aware that in some cases low statistical power, 
caused by a relatively small sample size, might lead to false 
findings. However, several highly significant associations with 
very narrow confidence intervals were observed, indicating a 
low probability of false-positive findings. To assess the pos-
sible confounding effects of the various clinical parameters, 
all variables that might have affected treatment outcomes were 
examined in the multivariable analyses. In addition, the use 
of different DNA sources for genotyping analysis might have 
influenced our results but, similar to our previous studies,12,14 
we confirmed a strong concordance between different DNA 
sample sources at the single-nucleotide level. Our observa-
tions were also in good agreement with studies that showed 
strong concordance between different DNA sample sources at 
the single-nucleotide level.51
The major strength of our study was a relatively homog-
enous patient cohort because only patients with MM treated 
with first-line gemcitabine-platinum combination chemo-
therapy were included. As treatment, outcome assessment, 
and follow-up were centralized for all included patients with 
MM, discrepancies in the clinical data collection procedure 
were minimized. Besides, our study was not biased by genetic 
heterogeneity because all the patients were recruited from a 
geographically limited area with an ethnically homogeneous 
population.52
In conclusion, our results support the hypothesis 
that DNA repair gene polymorphisms, particularly XRCC1 
Arg399Gln, may modulate the response to gemcitabine- 
platinum combination chemotherapy and, for the first time, 
show this effect in patients with MM. Although these find-
ings are of interest, they should be replicated in independent 
prospective studies to validate the importance of BER and 
HRR polymorphisms in gemcitabine-platinum combination 
chemotherapy treatment outcomes. Because response to any 
systemic chemotherapy in patients with MM is generally low, 
individualized chemotherapy strategies that allow selection 
of patients who would most likely benefit from gemcitabine-
platinum treatment should be considered.
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